(Q30418957)

English

The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study (English)

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

author name string

Chad A Hamilton

1

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Austin Miller

2

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Caela Miller

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Thomas C Krivak

4

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

John H Farley

5

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Mildred R Chernofsky

6

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Michael P Stany

7

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

G Scott Rose

8

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Maurie Markman

9

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Robert F Ozols

10

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Deborah K Armstrong

11

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

G Larry Maxwell

12

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

language of work or name

0 references

publication date

17 June 2011

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

122

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

521-526

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

The effect of primary cytoreduction on outcomes of patients with FIGO stage IIIC ovarian cancer stratified by the initial tumor burden in the upper abdomen cephalad to the greater omentum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Prognostic factors for complete debulking in first- and second-line ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Progress in gynecologic cancer research: the Gynecologic Oncology Group experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

"Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

28 July 2018

Role of surgery in ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

26 November 2018

The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

26 November 2018

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

26 November 2018

A critique of surgical cytoreduction in advanced ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3670691

26 November 2018

Aggressive surgical effort and improved survival in advanced-stage ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Cytoreduction vs. neoadjuvant chemotherapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Importance of surgical aggressiveness in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Aggressive surgery and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.04.041

7 January 2021

Identifiers

10.1016/J.YGYNO.2011.04.041

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

16 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30418957&oldid=1980568178"